US pharmaceutical company Merck & Co Inc (NYSE:MRK), known as MSD outside the US and Canada, announced on Tuesday that it has completed the acquisition of CN201, an investigational B-cell depletion therapy, from Curon Biopharmaceutical.
CN201 has potential applications in B-cell malignancies and autoimmune diseases.
CN201 is currently being studied in clinical trials for the treatment of non-Hodgkin's lymphoma and B-cell acute lymphocytic leukaemia. Preliminary data suggest that it is well-tolerated and may lead to significant reductions in B-cell populations.
Merck acquired full global rights to CN201 for approximately USD750m. This acquisition strengthens Merck's pipeline of potential treatments for B-cell associated diseases.
Henlius and Organon announce FDA acceptance of BLA for denosumab biosimilar, HLX14
Organon adds VTAMA cream to dermatology portfolio with acquisition of Dermavant
Redwire partners with Bristol Myers Squibb for space-based drug research
Accord Healthcare wins CHMP approval for Stelara biosimilar Imuldosa
Adicet Bio receives FDA clearance to expand ADI-001 trials to additional autoimmune diseases
Cantargia reports positive safety and biomarker results in CAN10 phase 1 trial
Lundbeck launches clinical trial for CD40L blocker Lu AG22515
Merck acquires CN201 from Curon Biopharmaceutical
Adicet Bio announces enrollment for Phase 1 trial to evaluate ADI-001 in autoimmune diseases